/INVA
INVA Stock - Innoviva, Inc.
Healthcare|BiotechnologyNASDAQ
$19.99-0.40%
$0.08 (-0.40%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.57
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+57.6%upside
Target: $31.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INVA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$19.79 – $20.19
TARGET (TP)$31.50
STOP LOSS$18.39
RISK/REWARD1:7.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.47
52W High$22.76
52W Low$16.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $358.71M | $310.46M | $331.34M | $391.87M | $336.79M |
| Gross Profit | $322.11M | $267.82M | $317.55M | $391.87M | $336.79M |
| Gross Margin | 89.8% | 86.3% | 95.8% | 100.0% | 100.0% |
| Operating Income | $166.87M | $113.89M | $-36,946,000 | $375.10M | $321.12M |
| Net Income | $23.39M | $179.72M | $213.92M | $265.85M | $224.40M |
| Net Margin | 6.5% | 57.9% | 64.6% | 67.8% | 66.6% |
| EPS | $0.37 | $2.92 | $3.07 | $3.24 | $2.21 |
Company Overview
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
60%
Hold / Neutral
1
20%
Sell / Underperform
1
20%
Analyst Consensus🟡 Mixed
3 Bullish2 Neutral/Bearish
Price Targets
$33
Average Target
↑ 65.9% Upside
Now
$16
Low
$33
Average
$55
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 30th 2025 | Goldman | Initiation | Sell | $17 |
| August 11th 2025 | Oppenheimer | Initiation | Outperform | $45 |
| July 14th 2025 | H.C. Wainwright | Initiation | Buy | $40 |
| July 11th 2025 | Cantor Fitzgerald | Initiation | Overweight | $26 |
| March 7th 2025 | Scotiabank | Initiation | Sector Outperform | $55 |
| June 18th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| July 20th 2022 | Goldman | Initiation | Neutral | $16 |
Earnings History & Surprises
INVABeat Rate
67%
Last 18 quarters
Avg Surprise
+63.5%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$1.08
Q4 2025
EPS Surprise History
Q1 24
+230.4%
$0.76vs$0.23
Q2 24
+170.6%
$0.46vs$0.17
Q3 24
+183.3%
$0.68vs$0.24
Q4 24
-92.6%
$0.02vs$0.27
Q1 25
+67.6%
$0.57vs$0.34
Q2 25
-13.8%
$0.25vs$0.29
Q3 25
+35.1%
$0.77vs$0.57
Q4 25
+134.8%
$1.08vs$0.46
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.34 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.46 | $1.08 | +134.8% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.57 | $0.77 | +35.1% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.29 | $0.25 | -13.8% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $0.34 | $0.57 | +67.6% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.27 | $0.02 | -92.6% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | $0.24 | $0.68 | +183.3% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.17 | $0.46 | +170.6% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.23 | $0.76 | +230.4% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $0.27 | $0.98 | +263.0% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $0.26 | $0.08 | -69.2% | ✗ MISS |
Q2 2023 | May 9, 2023 | $0.23 | $0.42 | +82.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $0.41 | $0.25 | -39.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $2.75 | $0.60 | -78.2% | ✗ MISS |
Q3 2022 | Jul 27, 2022 | $0.55 | $0.05 | -90.9% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $0.40 | $0.42 | +5.0% | ✓ BEAT |
Q1 2022 | Feb 9, 2022 | $0.41 | $0.55 | +34.1% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $0.43 | $0.90 | +109.3% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.29 | $0.90 | +210.3% | ✓ BEAT |
Latest News
HC Wainwright & Co. Maintains Buy on Innoviva, Raises Price Target to $46
📈 PositiveBenzinga•Dec 16, 2025, 12:00 PM
The FDA Today Approved Nuzolvence (Zoliflodacin) Granules That Dissolve In Water; Medicine Can Treat Uncomplicated Urogenital Gonorrhea In Adults And Children 12 Years And Older
📈 PositiveBenzinga•Dec 12, 2025, 06:27 PM
Reported Earlier, Innoviva Specialty Therapeutics Reports Phase 3 Zoliflodacin Results Published In The Lancet With FDA NDA Accepted In June And December 2025 PDUFA Target
📈 PositiveBenzinga•Dec 12, 2025, 08:25 AM
Innoviva shares are trading higher after the company reported better-than-expected Q3 financial results. Also, Cantor Fitzgerald raised its price target on the stock from $29 to $31.
📈 PositiveBenzinga•Nov 6, 2025, 04:48 PM
Cantor Fitzgerald Maintains Overweight on Innoviva, Raises Price Target to $31
📈 PositiveBenzinga•Nov 6, 2025, 02:42 PM
Innoviva Q3 EPS $1.08 Beats $0.52 Estimate, Sales $107.800M Beat $91.309M Estimate
📈 PositiveBenzinga•Nov 5, 2025, 09:47 PM
Innoviva Specialty Therapeutics To Present Analysis From Zoliflodacin Pivotal Phase 3 Trial At IDWeek 2025 Oct. 21
📈 PositiveBenzinga•Oct 20, 2025, 12:08 PM
Goldman Sachs Initiates Coverage On Innoviva with Sell Rating, Announces Price Target of $17
📉 NegativeBenzinga•Sep 30, 2025, 01:06 PM
Frequently Asked Questions about INVA
What is INVA's current stock price?
Innoviva, Inc. (INVA) is currently trading at $19.99 per share. The stock has moved -0.40% today.
What is the analyst price target for INVA?
The average analyst price target for INVA is $31.50, based on 1 analyst.
What sector is Innoviva, Inc. in?
Innoviva, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is INVA's market cap?
Innoviva, Inc. has a market capitalization of $1.29 billion, making it a small-cap company.
Does INVA pay dividends?
No, Innoviva, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATAI
Atai Beckley N.V
$3.96
Mkt Cap: $0.7B
CVAC
CureVac N.V.
$4.16
Mkt Cap: $0.9B
DNTH
Dianthus Therapeutics, Inc.
$42.44
Mkt Cap: $1.5B
ELVN
Enliven Therapeutics, Inc.
$16.87
Mkt Cap: $1.0B
IMTX
Immatics N.V.
$10.27
Mkt Cap: $1.2B
INBX
Inhibrx Biosciences, Inc.
$86.13
Mkt Cap: $1.3B
MDXG
MiMedx Group, Inc.
$7.05
Mkt Cap: $1.0B
NKTR
Nektar Therapeutics
$46.84
Mkt Cap: $1.0B
RLAY
Relay Therapeutics, Inc.
$8.40
Mkt Cap: $1.5B
SNDX
Syndax Pharmaceuticals, Inc.
$20.77
Mkt Cap: $1.8B
Explore stocks similar to INVA for comparison